COCONUT CREEK, Fla.--(BUSINESS WIRE)--July 22, 2013--
Greyson International Inc. (OTC Pink Sheets: GYSN), developer of an innovative patented topical delivery technology targeting the multi-billion dollar cosmetics and OTC pharmaceutical industries, today announced that talks with patent law firm Lerner Greenberg Stemer LLP resulted in across the board agreement with Greyson’s plan to help save and stave the potential $90+ billion loss in the pharmaceutical market.
Large pharmaceutical companies are facing a so-called “patent cliff”, whereby brand names drugs, once having delivered steady sales and profits are losing, or have already lost, their patent protection. Johnson and Johnson (NYSE:JNJ) has had three blockbuster drug patents expire in the last two years, Eli Lilly’s (NYSE:LLY) Cymbalta loses its patent at the end of 2013, and Pfizer (NYSE:PFE) recently attained a short extension on multibillion-dollar Celebrex which expires in Dec. 2015.
Lerner Greenberg Stemer LLP patent law firm for the world’s largest multinational corporations concur with Greyson’s plan to utilize their patented Trilexon(R) trans-dermal topical delivery system in several ways. “Leveraging our technology, large pharmaceutical companies can potentially reformulate their drugs to be delivered topically instead of orally, extend patent lives, and/or create new patents quickly under the Greyson umbrella” said Harvey Tauman, CEO of Greyson International Inc. “Greyson International, in addition to being debt free, has invested millions over a period of about 20 years culminating to the point whereby preparation is meeting opportunity.”
Currently Greyson International has anchored a large manufacturer, added two prominent physicians as consultants, and recruited top industry beauty consultants for Greyson Skincare(R) with Trilexon(R) technology. Their new spokesperson and brand manager, Tia Castle is preparing to launch Greyson Skincare line on network shopping television toward the fourth quarter of 2013. Greyson is open to adding new talent to the managerial team as it rapidly expands to meet market demands. All inquiries may contact Harvey Tauman.
Greyson International’s revolutionary patented Trilexon(R) delivery system allows the finest ingredients to be released topically over an extended period of time, while maintaining the skin’s natural intracellular barrier to promote natural moisture and lipid levels, providing a comfortable and durable experience that’s unlike anything else in the market.
About Greyson International, Inc.
Greyson’s primary focus is on its recently patented Trilexon(R) delivery system. In addition to cosmetic applications, Trilexon(R) may also have benefits in the medical field where it is important to deliver active ingredients. Trilexon(R) is a registered trademark of Greyson International Inc. For more information, visit our website; http://greysonintl.com and join the Greyson International’s Facebook page http://www.facebook.com/GreysonInternationalInc.
This release contains information about management’s view of our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with our financial condition, our ability to sell our products and our ability to compete with competitors. We encourage you to review other factors that may affect our future results on any current or future documents we file periodically with the Securities & Exchange Commission.